UK investigators create an international working party to help define Difficult-to-treat Psoriatic arthritis (D2T) in clinical practice and research.
Are you a rheumatologist working with Psoriatic arthritis? As you know, over 30% of patients with PsA do not respond to treatment with advanced biologic and targeted synthetic therapies, with a small group not responding to any of the treatments available.
We are trying to understand the reasons behind this, and would be grateful for your thoughts to help develop the research agenda in this area of unmet need.
Thanks for completing this short questionnaire:
The D2T PsA study group.